Wednesday - April 30, 2025

LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

RxSight to Present at the Bank of America Healthcare Conference

April 26, 2023 | Last Trade: US$15.24 0.68 4.67

ALISO VIEJO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

RxSight’s management is scheduled to present on Wednesday, May 10, 2023, at 3:55 p.m. Pacific Time / 6:55 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high-quality of vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley Thunen
RxSight, Inc.
949-521-7830
sthunen@rxsight.com

Investor Relations Contact:
ir@rxsight.com


Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page